Saturday, 31 October 2026European Markets

AKASTOR Stock Was 10.89% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with AKASTOR (AKAST.OL) jumping 10.89% to kr11.20 on Thursday while Oslo Børs Benchmark Index_GI rose 0.96% to kr1,210.13.

AKASTOR's last close was kr10.10, 28.57% below its 52-week high of kr14.14.

About AKASTOR

Akastor ASA operates as an oilfield services investment company in Norway, the United Kingdom, Denmark, Australia, and internationally. The company offers vessel-based subsea well construction and intervention services to the oil and gas industry. It also provides well design and drilling project management services; reservoir and field management services; and rig procurement, tailored training, software, and technical manpower services, as well as well and reservoir consultancy services. In addition, the company offers a range of offshore drilling equipment products and packages. It owns five offshore vessels. Akastor ASA was founded in 1841 and is based in Bærum, Norway.

Earnings Per Share

As for profitability, AKASTOR has a trailing twelve months EPS of kr-0.62.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.76%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.3%, now sitting on 1.07B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AKASTOR's EBITDA is -431.5.

More news about AKASTOR (AKAST.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com